European Commission Authorizes SKYRIZI for Younger Psoriasis Patients

The European Commission has approved SKYRIZI for children and adolescents aged six and older with moderate to severe plaque psoriasis. This decision, based on Phase 3 trial data, introduces a new systemic treatment option for younger patients with this chronic skin condition. A new syringe size will support weight-based dosing.